Answers are grounded in this paper and cite their sources.
Network pharmacology reveals luteolin's potential to target CDK1/Cyclin B in ER+ breast cancer stem cells, suggesting a new treatment avenue.
LT from VN shows promise as a therapeutic agent targeting CDK1/Cyclin B in ER+ breast cancer stem cells, supporting its potential for clinical development.
No takes yet. Share an insight, caveat, or question.
Basnet et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: